Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study
- Creator: Shapiro, Jeremy D. , Thavaneswaran, Subotheni , Tebbutt, Niall C. , Price, Timothy J. , Khasraw, Mustafa , Van Hazel, Guy A. , Waring, Paul M. , Tejpar, Sabine , Simes, John , Gebski, Val J. , Desai, Jayesh , Segelov, Eva , Underhill, Craig R. , Robledo, Kristy P. , Karapetis, Chistos S. , Day, Fiona L. , Nott, Louise M. , Jefford, Michael , Chantrill, Lorraine A. , Pavlakis, Nick
- Resource Type: journal article
- Date: 2018
When do patient reported quality of life indicators become prognostic in breast cancer?
- Creator: Lee, Chee Khoon , Hudson, Malcolm , Simes, John , Ribi, Karin , Bernhard, Jurg , Coates, Alan
- Resource Type: journal article
- Date: 2018